Einas Batarseh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Einas Batarseh has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Anna C. Pinelo
University at Buffalo, Buffalo, New York, and
2 shared publications- Brian P. Kersten
Buffalo General Medical Center, Buffalo, New York
2 shared publications Jamie N. Nadler
University at Buffalo, Buffalo, New York, and
2 shared publications- Stanley A. Schwartz
Division of Allergy, Immunology and Rheumatology, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Clinical and Translational Research Center, 875 Ellicott St., Buffalo, NY 14203, USA
2 shared publications - Dalia Shami
General Practice, AlMahabba Hospital, Madaba, JOR
1 shared publication - John M. Sousou
Internal Medicine, Lake Erie College of Osteopathic Medicine, Jacksonville, USA
1 shared publication
Latest Publications
- Open Access
- 7 January 2023
- Published by Springer Nature in Cureus
- Vol. 15 (1) , e33484
The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes
Diabetes mellitus is a metabolic disorder characterized by increased serum glucose due to errors in insulin production or response. The prevalence of diabetes mellitus has continued to rise globally over the years, with roughly 7079 persons per 100,000 expected to be impacted by 2030. A vast number of patients with diabetes mellitus experience unfavorable side effects such as weight gain, hypoglycemia, and hepatorenal toxicity from the several diabetic medications available. These adverse effects may result in life-threatening consequences with a high likelihood of occurrence; therefore, ongoing efforts continue to develop medications with improved tolerability and better glycemic control. Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT-2i) are examples of new innovative targeted therapies to manage diabetes mellitus and potentially improve cardiorenal conditions. This review article details the specific mechanisms of action, potential side effects, and cardiorenal benefits of GLP-1RA and SGLT-2i therapies to fully understand their roles in combating type 2 diabetes mellitus (T2D).
- 7 January 2023
- Published by Springer Nature in Cureus
- Vol. 15 (1) , e33484
Open AccessThe Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes
Diabetes mellitus is a metabolic disorder characterized by increased serum glucose due to errors in insulin production or response. The prevalence of diabetes mellitus has continued to rise globally over the years, with roughly 7079 persons per 100,000 expected to be impacted by 2030. A vast number of patients with diabetes mellitus experience unfavorable side effects such as weight gain, hypoglycemia, and hepatorenal toxicity from the several diabetic medications available. These adverse effects may result in life-threatening consequences with a high likelihood of occurrence; therefore, ongoing efforts continue to develop medications with improved tolerability and better glycemic control. Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT-2i) are examples of new innovative targeted therapies to manage diabetes mellitus and potentially improve cardiorenal conditions. This review article details the specific mechanisms of action, potential side effects, and cardiorenal benefits of GLP-1RA and SGLT-2i therapies to fully understand their roles in combating type 2 diabetes mellitus (T2D).
- Open Access
- 1 March 2021
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 203 (5) , 646-647
Reply to Chan and Majluf-Cruz: Is the Angioedema Associated with COVID-19 a Real Entity, a Mimic, or Both?
- 1 March 2021
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 203 (5) , 646-647
Open AccessReply to Chan and Majluf-Cruz: Is the Angioedema Associated with COVID-19 a Real Entity, a Mimic, or Both?
- Open Access
- 1 December 2020
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (11) , 1581-1584
Angioedema in African American Patients Hospitalized for COVID-19
- 1 December 2020
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (11) , 1581-1584
Open AccessAngioedema in African American Patients Hospitalized for COVID-19